Brief: Intercept Pharmaceuticals Expects To Incur About $16 Million In Restructuring Costs

Intercept Pharmaceuticals

23/06/2023 11:40

June 23 (Reuters) - Intercept Pharmaceuticals Inc
 ICPT.O :
    * INTERCEPT PHARMACEUTICALS INC: EXPECTS TO INCUR
APPROXIMATELY
$16 MILLION IN RESTRUCTURING COSTS
    * INTERCEPT PHARMACEUTICALS INC: EXPECTS MAJORITY OF
RESTRUCTURING
COSTS TO BE INCURRED DURING Q3 OF 2023
    * INTERCEPT PHARMACEUTICALS INC: EXPECTS VAST MAJORITY OF
WORKFORCE REDUCTIONS COMPLETED BY END OF 2023
    * INTERCEPT PHARMACEUTICALS INC: TARGETING A NET REDUCTION
IN
ANNUAL NON-GAAP ADJUSTED OPERATING EXPENSES OF ABOUT $140
MILLION - SEC FILING

Further company coverage:  ICPT.O 

 ((Reuters.Briefs@thomsonreuters.com;))